Ubs Group Ag Seres Therapeutics, Inc. Transaction History

Ubs Group Ag

$528 Billion
Q1 2025

A detailed history of Ubs Group Ag transactions in Seres Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 1,456,161 shares of MCRB stock, worth $10.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,456,161

Previous 342,317 325.38%

Holding current value

$10.6 Million

Previous $284,000 258.8%

% of portfolio

0.0%

Previous 0.0%

32 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$0.64 - $0.91 $712,860 - $1.01 Million	1,113,844 Added 325.38%	1,456,161 $1.02 Million
Q4 2024 Feb 14, 2025	BUY	$0.55 - $0.98 $169,357 - $301,763	307,922 Added 895.25%	342,317 $284,000
Q3 2024 Nov 14, 2024	SELL	$0.7 - $1.48 $116,431 - $246,169	-166,331 Reduced 82.86%	34,395 $32,000
Q2 2024 Aug 13, 2024	BUY	$0.56 - $1.19 $53,065 - $112,764	94,760 Added 89.42%	200,726 $144,000
Q1 2024 May 13, 2024	BUY	$0.75 - $1.56 $73,437 - $152,748	97,916 Added 1216.35%	105,966 $81,000
Q4 2023 Feb 09, 2024	SELL	$0.93 - $2.15 $147,020 - $339,887	-158,087 Reduced 95.15%	8,050 $11,000
Q3 2023 Nov 09, 2023	BUY	$2.33 - $5.07 $216,470 - $471,033	92,906 Added 126.87%	166,137 $395,000
Q2 2023 Aug 11, 2023	SELL	$4.67 - $6.55 $172,192 - $241,511	-36,872 Reduced 33.49%	73,231 $350,000
Q1 2023 May 12, 2023	SELL	$4.95 - $6.09 $550,172 - $676,879	-111,146 Reduced 50.24%	110,103 $624,000
Q4 2022 Feb 08, 2023	BUY	$5.09 - $9.05 $944,072 - $1.68 Million	185,476 Added 518.48%	221,249 $1.24 Million
Q3 2022 Nov 10, 2022	BUY	$3.5 - $7.2 $112,528 - $231,487	32,151 Added 887.66%	35,773 $229,000
Q2 2022 Aug 10, 2022	SELL	$2.7 - $7.62 $243,486 - $687,171	-90,180 Reduced 96.14%	3,622 $12,000
Q1 2022 May 16, 2022	BUY	$6.3 - $8.84 $561,600 - $788,024	89,143 Added 1913.35%	93,802 $668,000
Q4 2021 Feb 14, 2022	SELL	$6.02 - $11.43 $2.36 Million - $4.47 Million	-391,204 Reduced 98.82%	4,659 $39,000
Q3 2021 Nov 15, 2021	BUY	$5.46 - $22.6 $2.12 Million - $8.77 Million	387,885 Added 4861.93%	395,863 $2.76 Million
Q2 2021 Aug 13, 2021	SELL	$18.46 - $24.36 $4,061 - $5,359	-220 Reduced 2.68%	7,978 $190,000
Q1 2021 May 12, 2021	BUY	$17.66 - $28.92 $112,988 - $185,030	6,398 Added 355.44%	8,198 $168,000
Q4 2020 Feb 11, 2021	SELL	$23.25 - $37.73 $167,237 - $271,391	-7,193 Reduced 79.98%	1,800 $44,000
Q3 2020 Nov 12, 2020	BUY	$3.74 - $28.74 $31,015 - $238,340	8,293 Added 1184.71%	8,993 $255,000
Q2 2020 Jul 31, 2020	SELL	$3.04 - $6.2 $35,972 - $73,364	-11,833 Reduced 94.41%	700 $3,000
Q1 2020 May 01, 2020	SELL	$2.64 - $3.82 $73,455 - $106,287	-27,824 Reduced 68.94%	12,533 $45,000
Q4 2019 Feb 14, 2020	BUY	$2.99 - $4.42 $54,570 - $80,669	18,251 Added 82.56%	40,357 $139,000
Q3 2019 Nov 14, 2019	BUY	$2.29 - $4.16 $47,645 - $86,552	20,806 Added 1600.46%	22,106 $88,000
Q2 2019 Aug 14, 2019	SELL	$2.28 - $7.35 $1,595 - $5,145	-700 Reduced 35.0%	1,300 $4,000
Q1 2019 May 14, 2019	SELL	$4.83 - $7.21 $5,675 - $8,471	-1,175 Reduced 37.01%	2,000 $14,000
Q4 2018 Feb 14, 2019	BUY	$4.52 - $8.88 $10,734 - $21,090	2,375 Added 296.88%	3,175 $15,000
Q3 2018 Nov 14, 2018	SELL	$7.33 - $9.23 $14,660 - $18,460	-2,000 Reduced 71.43%	800 $6,000
Q2 2018 Aug 14, 2018	BUY	$6.91 - $9.55 $4,837 - $6,685	700 Added 33.33%	2,800 $24,000
Q1 2018 May 15, 2018	SELL	$7.34 - $11.16 $3,670 - $5,580	-500 Reduced 19.23%	2,100 $15,000
Q3 2017 Nov 14, 2017	SELL	$12.81 - $16.85 $31,871 - $41,922	-2,488 Reduced 48.9%	2,600 $42,000
Q2 2017 Aug 14, 2017	SELL	N/A	-260 Reduced 4.86%	5,088 $57,000
Q1 2017 Nov 14, 2017	BUY	N/A	5,348	5,348 $60,000

Others Institutions Holding MCRB

# of Institutions

Shares Held

39.4M

Call Options Held

103K

Put Options Held

53K

View Full List

About Seres Therapeutics, Inc.

Ticker MCRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 124,072,000
Market Cap $906M
Description
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. The company's lead product candidate is the SER-109, an oral microbiome therapeutic candidate that has completed Phase III clinical trial for the ...

More about MCRB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account